Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma

被引:11
作者
Kasai, Kazuhiro [1 ]
Ushio, Akira [1 ]
Kasai, Yukiho [1 ]
Sawara, Kei [1 ]
Miyamoto, Yasuhiro [1 ]
Oikawa, Kanta [1 ]
Takikawa, Yasuhiro [1 ]
Suzuki, Kazuyuki [1 ]
机构
[1] Iwate Med Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Morioka, Iwate 0208505, Japan
关键词
Cisplatin; DDPH; Hepatocellular carcinoma; Portal vein tumor thrombosis; Transarterial chemoembolization; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; DRUG-ELUTING BEADS; HEPATIC-ARTERY; LIVER-CANCER; EMBOLIZATION; DOXORUBICIN; SURVIVAL; TRIAL; MICROSPHERES; PROGNOSIS;
D O I
10.3748/wjg.v19.i14.2242
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To evaluate the efficacy of transarterial chemoembolization (TACE) using a suspension of a fine-powder formulation of cisplatin (DDPH) in lipiodol (LPD) in the treatment of hepatocellular carcinoma (HCC). METHODS: The subjects were 262 HCC patients treated with TACE using a DDPH-LPD suspension. The DDPH-LPD suspension was prepared by mixing 50 mg of DDPH into 10 mL of LPD. TACE was repeated when treated lesions relapsed and/or new hepatic lesions were detected. These patients received additional TACE using the same agent. TACE was repeated until complete regression of the tumor was obtained. The primary efficacy endpoint of the current study was the objective early response rate. Secondary efficacy endpoints were progression-free survival (PFS) and overall survival. RESULTS: The objective early response rate was 43.6%. Cumulative PFS rates-were 56.7% at 6 mo, 23.1% at 12 mo, 13.4% at 18 mo, and 10.5% at 24 mo. The median PFS was 6.6 mo. Cumulative survival rates were 90.6% at 6 mo, 81.9% at 12 mo, 70.5% at 24 mo, and 58.8% at 36 mo. Median survival time was 46.6 mo. All adverse reactions were controllable by temporary suspension of treatment. No serious complications or treatment-related deaths were observed. CONCLUSION: TACE using a suspension of DDPH in LPD may be a useful treatment for HCC. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码:2242 / 2248
页数:7
相关论文
共 39 条
[1]  
BOKEMEYER C, 1995, CANCER CHEMOTH PHARM, V35, P334, DOI 10.1007/BF00689454
[2]  
Child C G, 1964, Major Probl Clin Surg, V1, P1
[3]   Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study [J].
Dhanasekaran, Renumathy ;
Kooby, David A. ;
Staley, Charles A. ;
Kauh, John S. ;
Khanna, Vinit ;
Kim, Hyun S. .
HPB, 2010, 12 (03) :174-180
[4]   Comparison of Conventional Transarterial Chemoembolization (TACE) and Chemoembolization With Doxorubicin Drug Eluting Beads (DEB) for Unresectable Hepatocelluar Carcinoma (HCC) [J].
Dhanasekaran, Renumathy ;
Kooby, David A. ;
Staley, Charles A. ;
Kauh, John S. ;
Khanna, Vinit ;
Kim, Hyun S. .
JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (06) :476-480
[5]  
DOROSHOW JH, 1979, CANCER TREAT REP, V63, P855
[6]  
ITSUBO M, 1994, CANCER, V73, P298, DOI 10.1002/1097-0142(19940115)73:2<298::AID-CNCR2820730211>3.0.CO
[7]  
2-4
[8]  
Japan LCSGo, 2009, GEN RUL CLIN PATH ST
[9]   Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival [J].
Jemal, A ;
Clegg, LX ;
Ward, E ;
Ries, LAG ;
Wu, XC ;
Jamison, PM ;
Wingo, PA ;
Howe, HL ;
Anderson, RN ;
Edwards, BK .
CANCER, 2004, 101 (01) :3-27
[10]   Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: Comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion [J].
Kamada, K ;
Nakanishi, T ;
Kitamoto, M ;
Aikata, H ;
Kawakami, Y ;
Ito, K ;
Asahara, T ;
Kajiyama, G .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2001, 12 (07) :847-854